Study to compare effect of terbinafine alone versus terbinafine with MMR vaccine in case of difficult to treat fungal infection

Study to compare efficacy of terbinafine alone vs MMR vaccine and terbinafine in case of recalcitrant dermatophytosis

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/031654

Enrollment

Registered

2021-03-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Oral terbinafine with Inj MMR: tablet terbinafine 250 mg twice daily with injection MMR intramuscular and over lesion biweekly for two months Control Intervention1: Oral terbinafine: ta

Eligibility

Inclusion criteria

Inclusion criteria: recalcitrant dermatophytosis patients willing to participate in trial

Exclusion criteria

Exclusion criteria: not willing to participate in trial

Design outcomes

Primary

Measure	Time frame
Clinical cure in dermatophytosisTimepoint: 0 day . 15 day. 30 day , 45 day, 60 day	—

Secondary

Measure	Time frame
Clinical improvement in dermatophytosisTimepoint: 0 day . 15 day. 30 day , 45 day, 60 day	—

Countries

India

Contacts

Public ContactDr Shahrukh Panwar

MGM medical college and hospital Aurangabad

ashish7557@gmail.com9422213292

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026